Pfizer Inc. (TSX:PFE)
12.83
+0.02 (0.16%)
Nov 16, 2026, 1:48 PM EST
Pfizer Revenue
Pfizer had revenue of $16.58B USD in the quarter ending September 27, 2026, a decrease of -0.43%. This brings the company's total for the last twelve months to $63.63B, up 1.34% year-over-year. In the year 2025, Pfizer had annual revenue of $62.58B, down -1.65%.
Revenue (ttm)
$63.63B
Revenue Growth
+1.34%
P/S Ratio
2.64
Revenue / Employee
$848.33K
Employees
75,000
Market Cap
235.05B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Pfizer breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.58B | -1.05B | -1.65% |
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | 15.90B | 32.26% |
| Dec 31, 2009 | 49.27B | 973.00M | 2.01% |
| Dec 31, 2008 | 48.30B | -122.00M | -0.25% |
| Dec 31, 2007 | 48.42B | 47.00M | 0.10% |
| Dec 31, 2006 | 48.37B | 966.00M | 2.04% |
| Dec 31, 2005 | 47.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.21B |
| Extendicare | 2.17B |
| Curaleaf Holdings | 1.92B |
| Green Thumb Industries | 1.76B |
| WELL Health Technologies | 1.56B |
| Sienna Senior Living | 1.11B |
| Vireo Growth | 611.54M |
| Knight Therapeutics | 563.45M |
Pfizer News
- 4 days ago - Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug - Barrons
- 4 days ago - Pfizer now sees 2026 adjusted EPS $1.45-$1.54, consensus $2.00 - TheFly
- 4 days ago - Pfizer Slides: Investor presentation - Filings
- 4 days ago - Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development - WSJ
- 4 days ago - Pfizer secures up to $1.5 billion from Blackstone for obesity drug development - Reuters
- 4 days ago - Pfizer, Blackstone Life Sciences announce strategic co-funding agreement - TheFly
- 4 days ago - Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program - Business Wire
- 6 days ago - Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - Business Wire